Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | HAE | Common Stock | Award | +5.9K | 5.9K | May 2, 2022 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | HAE | Non-qualified Stock Option (Right to Buy) | Award | $0 | +13.8K | $0.00 | 13.8K | May 2, 2022 | Common Stock | 13.8K | $50.83 | Direct | F3 |
Id | Content |
---|---|
F1 | The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. |
F2 | Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
F3 | Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. |